Alkermes Plc
$ 33.31
-1.77%
24 Apr - close price
- Market Cap 5,551,110,000 USD
- Current Price $ 33.31
- High / Low $ 34.33 / 33.30
- Stock P/E 23.62
- Book Value 10.99
- EPS 1.41
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.07 %
- ROE 0.15 %
- 52 Week High 36.48
- 52 Week Low 25.17
About
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Analyst Target Price
$44.24
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-25 | 2025-10-23 | 2025-07-29 | 2025-05-01 | 2025-02-12 | 2024-10-24 | 2024-07-24 | 2024-05-01 | 2024-02-15 | 2023-10-25 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.29 | 0.6508 | 0.68 | 0.13 | 1.05 | 0.73 | 0.7 | 0.43 | 0.22 | 0.64 | 0.55 | 0.01 |
| Estimated EPS | 0.41 | 0.38 | 0.38 | 0.05 | 0.76 | 0.71 | 0.7 | 0.58 | 0.51 | 0.44 | 0.46 | -0.01 |
| Surprise | -0.12 | 0.2708 | 0.3 | 0.08 | 0.29 | 0.02 | 0 | -0.15 | -0.29 | 0.2 | 0.09 | 0.02 |
| Surprise Percentage | -29.2683% | 71.2632% | 78.9474% | 160% | 38.1579% | 2.8169% | 0% | -25.8621% | -56.8627% | 45.4545% | 19.5652% | 200% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.57 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALKS
2026-04-22 16:09:50
Alkermes plc (Nasdaq: ALKS) announced that it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. Interested parties can access the webcast on the Alkermes website.
2026-04-13 12:10:08
Tudor Investment Corp ET AL has acquired a new stake in Alkermes plc (NASDAQ:ALKS), purchasing 56,383 shares valued at approximately $1.69 million in the third quarter. Despite this institutional interest and other funds increasing their positions, insiders have been selling shares, with 159,468 shares worth $5.43 million sold in the last 90 days. Alkermes also missed Q2 earnings estimates, though analysts maintain a "Moderate Buy" rating with an average target price of $44.07.
2026-04-10 15:39:40
This article reports on an ARS filing by Alkermes plc. (ALKS) on April 6, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to Alkermes. The company's stock data, including market capitalization and industry, are also detailed.
2026-04-01 18:41:15
Alkermes (ALKS) has advanced alixorexton, an experimental oral treatment, into Phase 3 Brilliance Studies for narcolepsy types 1 and 2, building on positive Phase 2 results. The biotechnology company, with a market capitalization of $5.89 billion, demonstrates strong financial health despite recent insider selling. Investors should consider the company's robust balance sheet and moderate volatility alongside potential regulatory and competitive risks.
2026-02-18 12:58:25
Deutsche Bank has adjusted its price target for Alkermes plc (ALKS) from $43 to $42, while reiterating a Buy rating on the stock. This update reflects a minor change in the bank's valuation for the biopharmaceutical company. Alkermes recently completed the acquisition of Avadel Pharmaceuticals plc, expanding its presence in the sleep medicine market.
2026-02-17 18:27:45
Alkermes (ALKS) is positioned for another earnings beat in its upcoming quarterly report, thanks to a strong history of surpassing analyst estimates and a favorable Zacks Earnings ESP of +1.54%. The company's average surprise in the last two quarters was 21.75%, and with a Zacks Rank #1 (Strong Buy), there's a strong indication of a positive surprise. Investors are advised to watch for the earnings release on February 25, 2026.
